Drug Patent Watch

FEBRUARY 3, 2021

This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve….

Biosimilars 98

Biosimilars FDA Licensing Licensing 98

The Pharma Data

SEPTEMBER 10, 2021

This is the first marketing authorization globally for abrocitinib-. This is the first marketing authorization globally for abrocitinib-. Abrocitinib is licensed in Great Britain in recommended doses of 100mg and 200mg. This is the first marketing authorization worldwide for this treatment. “We

Marketing 52

Marketing Licensing Licensing Small Molecule 52

Drug Patent Watch

JANUARY 21, 2021

This article was first published by Elinevan Overbeeke, Sissel Michelsen, Mondher Toumi, Hilde Stevens, Mark Trusheim, Isabelle Huys, and StevenSimoens in Drug Discovery Today under a Creative Commons License. Highlights….

Therapies 52

Therapies Marketing Licensing Licensing 52

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. 7, 2021 /PRNewswire/ — ImaginAb Inc. , No other terms were disclosed.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Pfizer Inc.

Licensing 52

Licensing Licensing Vaccine FDA 52

SCIENMAG: Medicine & Health

JUNE 9, 2023

Virginia Tech Intellectual Properties (VTIP) with LINK + LICENSE + LAUNCH’s Proof-of-Concept Program has provided the springboard for faculty to bring their research to market. Over the past four years, the program has funded 24 Virginia Tech research projects. Credit: Photo by Luke Hayes for Virginia Tech.

Research 84

Research Licensing Licensing Marketing 84

ASPET

OCTOBER 12, 2023

The Countering Emerging Threats - Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) program within the JPM Medical is designed to rapidly tackle known, unknown, and emerging threats by utilizing late-stage or licensed therapeutics. Repurposing is one such method. CBRN MCMs).

Therapies 100

Therapies Licensing Licensing FDA Approval 100

Perficient: Drug Development

MARCH 25, 2025

Real technology spend includes observability tools, containers, data platforms, SaaS licensing, AI/ML, and peripheral services, sometimes hand-waved away as shadow IT or just life as part of an unavoidable cost center. Complexity is increasing: multicloud and hybrid environments are the norm.

Engineering 52

Engineering Production Licensing Licensing 52

The Pharma Data

APRIL 9, 2021

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability. Biogen Inc.

Biosimilars 52

Biosimilars Licensing Licensing Therapies 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

MAY 7, 2021

BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (together with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

FDA Law Blog: Biosimilars

JUNE 12, 2024

While that’s not to say that OTC hearing aids aren’t working to address the critical issue of hearing loss, it seems that almost two years is still not enough time to assess market impact, or to show that some of the promises of significant savings for large numbers of consumers have been realized.

FDA 111

FDA Regulations Treatment Licensing 111

Drug Target Review

APRIL 14, 2025

The antibiotic market has long faced significant barriers to innovation, with structural issues that make it difficult for new antibiotics to gain traction. As the demand for novel antibiotics remains limited due to the preference for cheaper generics, the market has struggled to incentivise much-needed breakthroughs.

Therapies 52

Therapies Marketing Drug Development Treatment 52

The Pharma Data

DECEMBER 20, 2020

Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology. Interventional treatment for mitral regurgitation is considered to be one of the most challenging areas in the field of structural heart disease, yet also represents huge market potential.

Licensing 40

Licensing Licensing Production Treatment 40

The Pharma Data

AUGUST 17, 2020

DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses. No forward-looking statement can be guaranteed.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. About Burning Rock.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

AUGUST 19, 2021

today announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now under evaluation with the European Medicines Agency (EMA).

Marketing 52

Marketing Treatment FDA FDA Approval 52

Fierce BioTech

MARCH 31, 2025

In todays challenging funding landscape, investors and partners demand more than regulatory milestones; they need a clear path to market differentiation and value creation. This expert panel will explore how early commercialization planning, powered by real-world insights, can maximize an assets potential.

Science 52

Science Licensing Licensing Marketing 52

Perficient: Drug Development

JANUARY 19, 2024

If you want to reduce capital and operational expenditures, speed time to market, and improve scalability, elasticity, security, and compliance, you should consider moving your on-premises IBM Sterling application to IBM supported native SaaS or other cloud solutions which best suits your business.

Compliance 118

Compliance Marketing Licensing Licensing 118

The Pharma Data

MARCH 30, 2021

There can be no guarantee that the FAP targeting agents, including FAPI-46 and FAPI-74, will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.

Therapies 52

Therapies Licensing Licensing Protein Expression 52

Drug Channels

OCTOBER 5, 2021

This 2021-22 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. reviews AmerisourceBergen’s entry into the European distribution market. (We Section 4.4. Section 7.4.4.

Pharmaceuticals 75

Pharmaceuticals Biosimilars Licensing Licensing 75

DS in Pharmatics

APRIL 4, 2025

can be complex, especially when determining whether a Biologics License Application (BLA) or a New Drug Application (NDA) is the appropriate route. While both serve as formal requests for market approval from the FDA, they apply to different types of [] Navigating the regulatory pathways for drug approvals in the U.S.

Licensing 52

Licensing Licensing FDA Marketing 52

Drug Channels

MARCH 15, 2022

Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

Drug Channels

FEBRUARY 21, 2023

As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. If you have any questions before purchasing a license to the report, please email me. d/b/a Drug Channels Institute.

Pharmacy 97

Pharmacy Specialty Pharmacies Licensing Licensing 97

Drug Target Review

NOVEMBER 25, 2024

I saw an opportunity which others didn’t, to develop a small molecule targeting a well-known cancer pathway, a master switch of cancer Afterwards, I moved to Germany to work for Merck KGaA, where I headed up the licensing and business development team. I would also advise anyone, young women and men included, to always believe in themselves.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

Drug Target Review

APRIL 23, 2024

The greater use of in silico methods is reflected in the growth of the computer-aided drug design (CADD) market, valued at $3.62 Licensing costs also need to be factored into the cost/benefit analysis, as the licensing terms of some commercial providers can severely limit the number of GPUs that can be used and hence the overall throughput.

Licensing 100

Licensing Licensing Drugs Drug Development 100

Drug Channels

OCTOBER 11, 2022

This 2022-23 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. The exhibits appear in all license versions. pharmaceutical distribution industry.

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

Perficient: Drug Development

SEPTEMBER 19, 2023

Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

Licensing 59

Licensing Licensing Production Marketing 59

The Pharma Data

NOVEMBER 4, 2020

Bactiguard’s growth strategy for the coming five-year period up to 2025 is based on a continued roll-out of Bactiguard’s technology, with a focus on new license agreements and a broader product portfolio. We have several interesting licensing projects ongoing and see new, exciting business opportunities. unchanged).

Licensing 52

Licensing Licensing Production Marketing 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. The high costs associated with bringing a new drug to market, estimated to be over $2.6

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Perficient: Drug Development

OCTOBER 27, 2023

Spartacus is an open-source JavaScript framework developed by SAP for building modern, responsive, and feature-rich e-commerce storefronts. The Composable Storefront emerged as an ideal solution for expedited market entry. This solution reduces time to market for SAP Commerce new implementations, upgrades, and migrations.

Compliance 105

Compliance Marketing Licensing Licensing 105

Perficient: Drug Development

NOVEMBER 10, 2023

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. Where the RDE Resides in a Program and the Deployment Lifecycle The RDE is generally available as an environment on a per-program basis.

Packaging 105

Packaging Licensing Licensing International 105

Agency IQ

JANUARY 4, 2024

Swissmedic reorg adds new focus on medical device market surveillance The Swiss regulator, Swissmedic, just announced a reorganization, with a new head of the medicinal product authorization and vigilance sector, but also a new and discrete medical devices surveillance sector. KAROLINE MATHYS is the head of the new sector.

Marketing 40

Marketing Regulations Clinical Trials International 40

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Laboratories 81

Laboratories FDA Regulations Licensing 81

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

Policy Prescription

OCTOBER 3, 2023

Salant’s paper supports personal drug importation and legalizing the importation of prescription drugs for commercial use so that wholesale pharmacies, including companies like Amazon and Costco, could tap into the parallel importation markets of other countries. drug market is connected to foreign markets with lower drug prices.

Pharmacy 84

Pharmacy International FDA Approval Government 84